导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 10.98% | 660/4773 |
| 近一周 | -4.03% | 4414/5458 |
| 近一月 | -9.55% | 4795/5421 |
| 近一季 | -8.43% | 3767/5205 |
| 近半年 | 8.37% | 588/4920 |
| 近一年 | 13.57% | 755/4361 |
| 近两年 | 99.85% | 617/2954 |
| 近三年 | 53.16% | 506/2253 |
| 成立以来 | 117.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.88% 2946/4961 |
47.08% 657/5312 |
- - |
- - |
| 2025 | 40.31% 780/4813 |
4.33% 956/3635 |
1.57% 2276/4076 |
37.41% 911/4524 |
-3.64% 3310/4813 |
| 2024 | 4.45% 1877/3463 |
-6.05% 2000/2808 |
-5.38% 1707/3014 |
16.52% 1430/3129 |
0.83% 1161/3463 |
| 2023 | -8.97% 1078/2656 |
13.67% 262/2280 |
-4.10% 1044/2385 |
-11.32% 2051/2515 |
-5.85% 1525/2655 |
| 2022 | -26.53% 1413/2207 |
-19.90% 1504/1919 |
5.05% 945/2016 |
-16.78% 1500/2113 |
4.92% 502/2208 |
| 2021 | 14.07% 343/1822 |
-6.00% 970/1255 |
21.19% 138/1330 |
-5.99% 888/1466 |
6.51% 213/1822 |
| 2020 | 80.21% 42/1250 |
5.93% 49/1028 |
25.44% 154/1067 |
13.12% 344/1164 |
19.89% 66/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 申万菱信中证研发创新100ETF VS. 长安沪深300非周期A(740101) |